- Home
- MGNX
MGNX
MacroGenics Inc.
as 08-28-2025 4:00pm EST
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | Rockville |
| Market Cap: | 99.7M | IPO Year: | 2013 |
| Target Price: | $3.25 | AVG Volume (30 days): | 582.9K |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.99 - $5.10 | Next Earning Date: | 08-14-2025 |
| Revenue: | $165,495,000 | Revenue Growth: | 303.47% |
| Revenue Growth (this year): | -52.37% | Revenue Growth (next year): | -36.42% |
Stock Insider Trading Activity of MacroGenics Inc. (MGNX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| HEIDEN WILLIAM K | MGNX | N/A | Aug 20 '25 | Buy | $1.49 | 49,500 | $73,755.00 | 111,000 | |
| HEIDEN WILLIAM K | MGNX | N/A | Aug 19 '25 | Buy | $1.52 | 50,500 | $76,760.00 | 111,000 |
Latest MacroGenics Inc. News
MGNX Breaking Stock News: Dive into MGNX Ticker-Specific Updates for Smart Investing
MT Newswires
3 months ago
MacroGenics, Sagard Sign Zynyz Royalty Purchase Deal
GlobeNewswire
3 months ago
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement
GlobeNewswire
3 months ago
MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
Zacks
3 months ago
Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies
Zacks
3 months ago
4 Medical Product Stocks to Watch From a Challenging Industry
MT Newswires
3 months ago
B. Riley Cuts Price Target on MacroGenics to $3 From $5, Keeps Neutral Rating
Simply Wall St.
3 months ago
Earnings Release: Here's Why Analysts Cut Their MacroGenics, Inc. (NASDAQ:MGNX) Price Target To US$4.50
Zacks
4 months ago
MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates
Compare MGNX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MGNX MacroGenics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.